Clinical trials: Still's Disease, Adult-Onset
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
The aim of this study is to demonstrate the efficacy and to evaluate the safety, pharmacokinetics (PK) and immunogenicity of anakinra in patients with newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic…
- Trial name
- anaSTILLs (NCT03265132)
- Testing
- anakinra
- Where
- 39 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Swedish Orphan Biovitrum
Adult Onset Still's Disease
A Study to Evaluate Camoteskimab in Participants With Still's Disease
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
- Trial name
- NCT04752371
- Testing
- Camoteskimab (CERC-007, AVTX-007, AEVI-007)
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 5 people
- Sponsor
- Apollo Therapeutics Ltd
Adult-Onset Still's Disease
Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study
An open, randomized, parallel-group, comparative, multicentre study. Patients on corticosteroids (plus conventional therapy) will be randomized to receive anakinra (Kineret®), or one of the following: methotrexate, azathioprine…
- Trial name
- NordicAOSD05 (NCT01033656)
- Testing
- anakinra, comparators
- Where
- Sweden
- Volunteers
- 23 people
- Sponsor
- University of Helsinki
Adult-Onset Still Disease, Critically Ill
Admission of Adult-onset Still Disease Patients in the ICU
Since its first description in 1971, diagnosing adult-onset Still's disease (AOSD), a rare multisystemic disorder considered as a multigenic autoinflammatory syndrome, remains challenging.
- Trial name
- Still-ICU (NCT03276650)
- Testing
- data collection
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Central Hospital, Nancy, France
Still's Disease, Adult-Onset
A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease
The purpose of this study is to compare the efficacy and safety of firsekibart versus anakinra in patients with AOSD.
- Trial name
- NCT07191444
- Testing
- Firsekibart, Anakinra
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Systemic Juvenile Idiopathic Arthritis (sJIA), Adult Onset Still's Disease (AOSD)
An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)
The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD).The study consists of up to four weeks…
- Trial name
- NCT07706868
- Testing
- Anakinra (Kineret®)
- Sponsor
- Swedish Orphan Biovitrum
Still's Disease Adult Onset
An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease
This is a randomized single-blind comparative parallel group study of the efficacy and safety of canakinumab biosimilar GNR-086 (JSC \"GENERIUM\", Russia) and Ilaris® (Novartis Pharma Stein AG, Switzerland) in the…
- Trial name
- NCT06497491
- Testing
- GNR-086, Ilaris®
- Where
- 17 sites in Russia
- Volunteers
- 118 people
- Sponsor
- AO GENERIUM
Adult Onset Still's Disease
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD
This study was designed to evaluate the efficacy and safety of canakinumab administered subcutaneously every 4 weeks for at least 48 weeks in Japanese patients with Adult-Onset Still's Disease (AOSD).
- Trial name
- NCT04717635
- Testing
- Canakinumab
- Where
- 9 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset
Assessment of Macrophage Activation syndromE in STill's Disease in Italy
Assessment of macrophage activation syndrome in Still's disease: retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy
- Conditions
- Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset, Still's Disease, Adult-Onset
- Trial name
- AMETISTA (NCT06992505)
- Where
- 2 sites in Italy
- Volunteers
- 32 people
- Sponsor
- Swedish Orphan Biovitrum
Adult Onset Still Disease
Evaluation of Adult Onset Still Disease Classification Criteria and Differential Diagnosis at Eighteen Months of Follow-up
Adult Onset Still Disease (AOSD) is an acquired inflammatory disease of unknown etiology, presenting with non specific symptoms. Its diagnosis rely on sets of criteria, i.e. Fautrel Criteria and Yamaguchi Criteria.
- Trial name
- AOSD-DIF (NCT04750863)
- Testing
- diagnosis criteria performance
- Volunteers
- 312 people
- Sponsor
- Central Hospital, Nancy, France
Still's Disease, Adult-Onset, Sepsis
Glycosylated Ferritin in Macrophagic Activation Syndromes
In healthy subjects, from 50 to 80 % of the serum ferritin is glycosylated [1, 2] . A decrease in the percentage of ferritin glycosylation can be observed in inflammatory diseases, malignancies, infections, or liver disease but…
- Conditions
- Still's Disease, Adult-Onset, Sepsis, Macrophagic Activation Syndrome
- Trial name
- FERRITGLY01 (NCT02143986)
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Brugmann University Hospital
Still's Disease, Adult-Onset
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3
This will be a single centre, Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of APB-R3 in Healthy…
- Trial name
- NCT05715736
- Testing
- APB-R3
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Still´s Disease
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
- Trial name
- NCT07203001
- Testing
- MAS825
- Where
- 23 sites in United States, Canada and 6 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Adult-Onset Still's Disease, AOSD
Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
The primary objective of the study is to evaluate the efficacy of RPH-104 when administered at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W) subcutaneous (SC) in patients with Adult Onset Still's…
- Trial name
- NCT05432960
- Testing
- RPH-104
- Where
- 4 sites in Russia
- Sponsor
- R-Pharm International, LLC
Still Disease, Still's Disease, Adult-Onset
Acostill ( RaDiCo Cohort) (RaDiCo Acostill)
Adult Onset Still Disease (AOSD) and Systemic onset Juvenile Idiopathic Arthritis (SoJIA) are two rare multifactorial diseases associated with systemic inflammation.
- Conditions
- Still Disease, Still's Disease, Adult-Onset, Still Disease, Juvenile Onset
- Trial name
- Acostill (NCT05927454)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Macrophage Activation Syndrome, Still's Disease, Adult-Onset
Assessment of Macrophage Activation syndromE in STill's Disease
Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics
- Conditions
- Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
- Trial name
- AMETHYST (NCT06405152)
- Testing
- Chart review
- Where
- 11 sites in United States, Canada and 5 more
- Volunteers
- 75 people
- Sponsor
- Swedish Orphan Biovitrum
Familial Mediterranean Fever, Still Disease
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including…
- Conditions
- Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease
- Trial name
- NCT07517250
- Where
- Switzerland
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Still's Disease, Adult-Onset
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
The objective of this study is to assess safety, tolerability and early signs of efficacy of the investigational drug Tadekinig alfa in Adult-onset Still's disease, a rare polygenic auto-inflammatory disorder for which treatment…
- Trial name
- NCT02398435
- Testing
- Tadekinig alfa (recombinant human IL-18 binding protein)
- Where
- 20 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- AB2 Bio Ltd.
Adult-Onset Still's Disease
Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease
This study aims to further evaluate the anti-inflammatory effects of the mTOR inhibitor sirolimus in patients with adult-onset Still's disease (AOSD), and to verify whether it can reduce inflammation and control disease activity…
- Trial name
- NCT07151157
- Testing
- add-on sirolimus therapy
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Ruijin Hospital
Inflammation, Familial Mediterranean Fever
Interleukin-1 Trap to Treat Autoinflammatory Diseases
Autoinflammatory diseases are illnesses characterized by episodes of inflammation that, unlike autoimmune disorders, lack the production of high titer autoantibodies or antigen-specific T cells.
- Conditions
- Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
- Trial name
- NCT00094900
- Testing
- IL-1 Trap
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)